Hospice High Dollar Medications and Possible Alternatives

Size: px
Start display at page:

Download "Hospice High Dollar Medications and Possible Alternatives"

Transcription

1 Hospice High Dollar Medications and Possible Alternatives Ly M. Dang, PharmD Director of Pharmacy Operations Hospice Pharmacy Solutions

2 Topics of Discussion Hospice Coverage per CMS Guidelines Buckets of Relatedness Evaluating for Medical Necessity Rescheduling of Hydrocodone combinations DEA Controlled Substance Prescribing/Dispensing Common High Dollar Drugs

3 Drugs and Biologicals Covered Under the Hospice Benefit Under Medicare Hospice Benefit, patients receive treatments and interventions to minimize symptoms, and maximize comfort and quality of life. By electing hospice, patients have chosen to move from a curative model of care to a holistic palliative model of care. Federal regulations at 42 CFR (f) hospice covers drugs and biologicals used primarily for the relief of pain and symptom control for the terminal illness and related conditions.

4 Hospice Responsibility Pay for ALL drugs related to the terminal illness and related conditions Conduct medication review during admission process and comprehensive assessment Develop a plan for discontinuing medications and communicating discontinuation decisions

5 Buckets of Relatedness

6 Rescheduling of Hydrocodone combinations Effective October 6, 2014 Hydrocodone combinations will be Schedule II Hydrocodone/apap ie. Vicodin, Lortab, Norco, etc Hydrocodone/IBU ie. Vicoprofen Hydrocodone cough suppressant ie Tussionex, Hycodan, etc Prescriptions written prior to October 6 th with refills are valid up until April 8, 2015

7 Required elements of a valid prescription Full name and address of the patient Drug name, strength, dosage form, quantity prescribed and directions Name, address and registration number of the practitioner Practitioner s signature Dated and signed on the day when issued

8 Fax CII Orders ONLY for residents in LTC or Medicare hospice program Prescription must state Hospice Patient

9 Oral Emergency CII Only in emergency situations. Immediate administration of the controlled drug is necessary for proper treatment of the intended ultimate user No appropriate alternative available Not reasonably possible for prescribing practitioner to provide written prescription Quantity prescribed and dispensed is limited to amount adequate to treat the patient during emergency period Prescriber must present written prescription to dispensing pharmacist within 7 days Written prescription must have date of oral order and Authorization for Emergency Dispensing If mailed, must be postmarked within 7 days If prescriber fails to comply, pharmacist is required to notify DEA If pharmacist fails to notify DEA, the pharmacist or pharmacy may lose license to dispense emergency orders

10 Reorders and Partial fill for CII Prescriber may issue multiple prescriptions for the same CII up to 90 day supply Include written instructions on each indicating earliest date to fill Partial Fills Only for LTC or terminally ill patients Prescription is valid for 60 days from date of issue

11 Evaluating for Medical Necessity Life expectancy Time until benefit Risk vs benefit ratios Goals of care Treatment targets

12 Appetite Stimulant Evaluate for any actual weight gain or increased appetite. Megace (megesterol) Consider discontinuation if not effective to reduce pill burden and potential side effects (ie DVT, edema). Symptomatic improvement in appetite may be seen in less than one week, but weight gain (which only occurs in one-fourth of treated patients) may take 6-12 weeks. Periactin (cyproheptadine) Consider discontinuation if not effective after ~4 weeks.

13 Supplements Evaluate multivitamins for any benefit in terms of survival, quality of life or symptom control versus the potential side effects of nausea or constipation. Iron supplements can cause gastric discomfort and constipation and these side effects may outweigh the benefits of iron supplementation at end of life. Calcium + D - evaluate the risk of fracture in this patient and consider discontinuing to reduce pill burden since the time needed to see a benefit may exceed the life expectancy of the patient.

14 Cholesterol Medications The time needed to see a benefit (usually measured in years) may exceed the life expectancy of the patient. Statins - The potential side effects such as muscle pain or confusion may outweigh any benefit at end of life. Fish Oil Supplements - The potential side effects such as diarrhea may outweigh any benefit at end of life. Fenofibrate - The potential side effects such as headache may outweigh any benefit at end of life. Cholestyramine Possibility of interference with the absorption of many other medications. Zetia Not actually proven to reduce stroke/heart attacks.

15 Cognitive Enhancers/Dementia Meds The American Geriatric Society recommends discontinuing cognitive enhancers when the FAST score = 7 if consistent with the goals of care. When possible consider tapering the medication gradually instead of stopping abruptly in case behavior issues develop. Evaluate the benefit of Namenda, Aricept, Exelon and Razadyne in end-stage, advanced dementia versus potential side effects such as anorexia, nausea, diarrhea and insomnia. Recent controlled trials do not demonstrate significant advantages to the combination of Namenda and Aricept to Aricept alone in patients with severe dementia. Evaluate the benefit of continuing Axona and Cerefolin in advanced dementia. According to the American Geriatric Society Axona has insufficient evidence to support its value in preventing or treating dementia and long-term effects are uncertain.

16 Pulmonary Medications Inhalers Inhaler technique is patient able to actuate the inhaler? Performance status is patient able to inhale deep enough to get medications to the lung? Daliresp - is indicated to prevent COPD exacerbations but doesn t actually treat any symptoms or help the patient breath better. The number of patients needed to treat (NNT) with Daliresp to prevent one moderate exacerbation per year was 5. The time needed to see a benefit from Daliresp may exceed the life expectancy of the patient. Evaluate the benefit versus the risk of side effects such as nausea, diarrhea and weight loss and consider discontinuing Daliresp.

17 Pulmonary Beta Agonist Bronchodilator Short acting Proair/Ventolin HFA MDI $60 Albuterol Nebs $20 Xopenex (levalbuterol) Nebs $120 Xopenex HFA MDI $60 Long acting Foradil DPI $240 Serevent DPI $240 Brovana Nebs $620 Perforomist Nebs $610

18 Pulmonary Anticholinergic Bronchodilator Short acting anticholinergic Atrovent Nebs (ipratropium) $25 Atrovent HFA Respimat $280 Long acting anticholinergic Spiriva $330 Tudorza $300

19 Pulmonary Corticosteroids Corticosteroids Asmanex DPI $200 Flovent HFA MDI $200 Flovent Diskus DPI $120 Pulmicort INH DPI $200 Pulmicort (budesonide) Nebs $265

20 Pulmonary - combination Short acting Beta Agonist + Anticholinergic Duoneb (albuterol/ipratropium) Nebs $30 Combivent INH $300 Long acting Beta Agonist + Corticosteroids Advair $420 Symbicort $280 Dulera $260

21 Long Acting Opioids

22 Immediate Release Opioids Drug Morphine 20mg/ml Oxycodone 20mg/ml Hydromorphone Cost $30 for 30ml $200 for 30ml $15 for 30 tabs

23 Fentanyl Patches Fentanyl patch dose Cost per box of 5 Fentanyl 12mcg $120 Fentanyl 25mcg $50 Fentanyl 50mcg $70 Fentanyl 75mcg $90 Fentanyl 100mcg $110

24 Nausea and Vomiting Drug/dose/dosage form Cost per dose Prochlorperazine 10mg tabs $0.30 Prochlorperazine 25mg supp $8.00 Promethazine 25mg tabs $0.20 Promethazine 25mg supp $8.00 Ondansetron 4mg tab $0.30 Ondansetron 4mg ODT $2.00

25 Psychosis Zyprexa (olanzapine) Risperdal (risperidone) Seroquel (quetiapine) $0.75/5mg Zyprexa Zydis $1.25/5mg $0.25/1mg Risperdal M tabs $3.00/1mg $0.70/200mg Seroquel XR $25.00/400mg

26 Terminal Secretions Atropine drops Hyoscyamine Transderm Scop patch Robinul (glycopyrrolate) $20 per 5ml (20drops/ml) $1 per tab $20 per patch $1 per tab

27 Questions Ly M. Dang, PharmD Director of Pharmacy Operations Hospice Pharmacy Solutions

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects

More information

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution

More information

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

STRIVERDI RESPIMAT (olodaterol hcl) aerosol STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Commissioner for the Department for Medicaid Services Selections for Preferred Products Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for

More information

LIGHTENING THE LOAD Reducing pill burden with appropriate discontinuation strategies

LIGHTENING THE LOAD Reducing pill burden with appropriate discontinuation strategies LIGHTENING THE LOAD Reducing pill burden with appropriate discontinuation strategies Disclaimer Statement This presentation is for educational purposes only. It is not intended as legal or professional

More information

MDI Bonanza. Dwayne Griffin, DO

MDI Bonanza. Dwayne Griffin, DO MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing

More information

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the

More information

Nancy Davis, RRT, AE-C

Nancy Davis, RRT, AE-C Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

Foundations of Pharmacology

Foundations of Pharmacology Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids

More information

End Stage COPD Guidance Document

End Stage COPD Guidance Document End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL* Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy

More information

Provider Respiratory Inservice

Provider Respiratory Inservice Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Common Inhaled Asthma Medications Dose Comparison and Tips for Use

Common Inhaled Asthma Medications Dose Comparison and Tips for Use Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications

More information

Diagnosis and Management of Asthma

Diagnosis and Management of Asthma Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:

More information

Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN

Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Goals of Therapy Asthma Prevent symptoms COPD Reduce COPD symptoms Decrease use of SABAs Maintain normal pulm function & prevent loss

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Medications Affecting The Respiratory System

Medications Affecting The Respiratory System Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The

More information

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints

More information

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18 Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Select Inhaled Respiratory Agents

Select Inhaled Respiratory Agents Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Hospice Pharmacotherapy 101: Cardio-Pulmonary Symptom Management

Hospice Pharmacotherapy 101: Cardio-Pulmonary Symptom Management Hospice Pharmacotherapy 101: Cardio-Pulmonary Symptom Management Katherine Sauer, PharmD, BCACP, CDE Clinical Pharmacist Hospice Pharmacy Services Disclosure I have no relevant financial relationships

More information

Great Low Cost in SNF-NF Jabbar Fazeli, MD Maine Medical Directors Association

Great Low Cost in SNF-NF Jabbar Fazeli, MD Maine Medical Directors Association Great Care @ Low Cost in SNF-NF Jabbar Fazeli, MD Maine Medical Directors Association Principles Best interest of the patient (SNF) and resident (NF) comes first. Lowest cost to achieve the same care.

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,

More information

Learning Objectives 4/26/2012. Review normal lung function and COPD pathophysiology Discuss pharmacological management

Learning Objectives 4/26/2012. Review normal lung function and COPD pathophysiology Discuss pharmacological management Marliese Gibson PharmD HospiScript, a Catalyst Rx Company May 16, 2012 Chronic Obstructive Pulmonary Disease Learning Objectives Review normal lung function and COPD pathophysiology Discuss pharmacological

More information

Assessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)

Assessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD) William P. Saliski Jr. DO Montgomery Pulmonary Consultants Management of Stable COPD Pharmacotherapy Oxygen Smoking Cessation Vaccinations Rehabilitation Surgery Future Discussions Assessing Severity Staging

More information

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules

More information

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly

More information

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

FASENRA (benralizumab)

FASENRA (benralizumab) FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Navigating the Road to Efficient Medication Use

Navigating the Road to Efficient Medication Use Navigating the Road to Efficient Medication Use Molly R. Sinert, RPh, PharmD Clinical Pharmacist HospiScript Services LLC a Catamaran Rx Company October 28, 2013 Objectives Describe the components of the

More information

Respiratory Medications and Devices Update 2/15

Respiratory Medications and Devices Update 2/15 Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient

More information

California. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

MANAGING ASTHMA. Nancy Davis, RRT, AE-C MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma

More information

Chronic Obstructive Pulmonary Disease (COPD) October Highlights:

Chronic Obstructive Pulmonary Disease (COPD) October Highlights: Spectrum of Health October 2016 Chronic Obstructive Pulmonary Disease (COPD) Highlights: Current standards in the screening and management of patients with COPD HEDIS requirements measuring COPD management

More information

Women Beware-The Threat of COPD

Women Beware-The Threat of COPD Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE: LEVALBUTEROL HFA (levalbuterol tartrate) inhalation aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

2014 Quantity Limits (QL) Criteria

2014 Quantity Limits (QL) Criteria 2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food

More information

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent Pain may be effectively managed through the use of controlled substance medications (referred to below as opioids

More information

Inhalation devices, proper technique and cleaning

Inhalation devices, proper technique and cleaning Preventing Your Symptoms and Taking Your Medications Inhalation devices, proper technique and cleaning Knowing how to use your medications properly is important because inhaled drugs are meant to get directly

More information

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32

More information

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction

More information

Presented by UIC College of Nursing

Presented by UIC College of Nursing Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.

More information

Chronic Obstructive Pulmonary Disease 1/18/2018

Chronic Obstructive Pulmonary Disease 1/18/2018 Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.

More information

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Improving Outcomes in COPD

Improving Outcomes in COPD Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea

More information

Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this

More information

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol) Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:

More information

10 mg hydrocodone equals how much oxycodone

10 mg hydrocodone equals how much oxycodone Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)

More information

New Hampshire Healthy Families CLINICAL POLICY

New Hampshire Healthy Families CLINICAL POLICY New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:

More information

ORAL MEDS FOR PAIN. Pain Tolerance 4/11/2018

ORAL MEDS FOR PAIN. Pain Tolerance 4/11/2018 ORAL MEDS FOR PAIN Pain Tolerance Varies with each individual Signs usually should match symptoms Have compassion but don t panic when someone appears to be in pain 1 The Psychology of Pain A firm, calm,

More information

Pequot Health Care Smart Quantity Program*

Pequot Health Care Smart Quantity Program* Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Smart Quantity Program* Updated January 2018 *Quantity Program limits apply to

More information

National Council on Patient Information and Education

National Council on Patient Information and Education National Council on Patient Information and Education You are not alone The type of pain that caused your doctor to prescribe a pain medicine for you can make you feel that you are different from everyone

More information

COPD. Stan Kellar, MD. Physiology 11/4/2014. Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine

COPD. Stan Kellar, MD. Physiology 11/4/2014. Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine Stan Kellar, MD Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine COPD Physiology The lungs are filters Filter in oxygen Filter out carbon dioxide (Vascular filter, not part of this discussion)

More information

Key features and changes to these four components of asthma care include:

Key features and changes to these four components of asthma care include: Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding

More information

Student Paper PHARMACY PRACTICE. Keywords: asthma, inhalers, patient education

Student Paper PHARMACY PRACTICE. Keywords: asthma, inhalers, patient education Assessment of Asthma Inhaler Technique in Two Community Pharmacies Nicole Farabaugh, PharmD Candidate; Ashlee McMillan, PharmD, BCACP; and Gretchen Garofoli, PharmD, BCACP WVU School of Pharmacy Keywords:

More information

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives. Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate

More information

10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C

10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines

More information

History & Development

History & Development RSPT 2317 Anticholinergic Bronchodilators () History & Development Prototypical parasympatholytic agent is atropine an alkaloid found naturally in the plants Atropa belladona (nightshade) and Datura species

More information

To Cover or Not To Cover? A Review of Medication Coverage Guidelines. Dr. Sherita D. Castille, Pharm D Clinical Pharmacist. Agenda.

To Cover or Not To Cover? A Review of Medication Coverage Guidelines. Dr. Sherita D. Castille, Pharm D Clinical Pharmacist. Agenda. To Cover or t To Cover? A Review of Medication Coverage Guidelines Dr. Sherita D. Castille, Pharm D Clinical Pharmacist Agenda 2 Overview Define key Medicare terms Determine relatedness to terminal prognosis

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Women Beware The Threat of COPD

Women Beware The Threat of COPD Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education

More information

Drug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources

Drug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources Drug Utilization Review & Cost Reduction Strategies Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources Goals and Objectives Define Drug Utilization Reviews Interpret various performance

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan See Important Reminder

More information

Your Inhaler Devices & You

Your Inhaler Devices & You 1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE

More information

Opioid Management Program October 2018

Opioid Management Program October 2018 Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of

More information

Knock Out Opioid Abuse in New Jersey:

Knock Out Opioid Abuse in New Jersey: Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids

More information

Correct Use of Inhaler Devices

Correct Use of Inhaler Devices PL Detail-Document #300206 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Correct Use of

More information

JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEO RDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY

JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEO RDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEO RDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY HERE ARE TODAY S CATEGORIES Theme Timer Correct Wrong Boo Silence Pharmacology Theme Timer Correct Wrong

More information

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation. Pharmacy Law 2016 Ronda H. Lacey, J.D., M.S. Pharm Disclosure Statement I have no conflicts of interest to disclose related to this presentation. Objectives At the conclusion of this continuing education

More information

Buprenorphine Access in California

Buprenorphine Access in California Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical

More information

Asthma COPD Update 2018

Asthma COPD Update 2018 Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State

More information

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor

More information

Asthma. Definition. Symptoms

Asthma. Definition. Symptoms Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some

More information

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma

More information

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC) Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC) May 2018 THE WATERLOO WELLINGTON SYMPTOM MANAGEMENT GUIDELINE FOR THE END OF

More information

Secretary for Health and Family Services Selections for Preferred Products

Secretary for Health and Family Services Selections for Preferred Products Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based

More information

Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control

Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control Erin Zimny, MD Emergency Medicine Hospice and Palliative Medicine Henry Ford Hospital Disclosures I do NOT have any financial

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Quality Department Guidelines for Clinical Care Ambulatory COPD Guideline Team Team Leader Davoren A Chick, MD General Medicine Team Members Paul J Grant, MD General Medicine R Van Harrison, PhD Learning

More information

Opioid Management Program May 2018

Opioid Management Program May 2018 Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily

More information